Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nuvo Research Inc Announces FDA Accepted Pennsaid 2% New Drug Application For Review


Thursday, 22 Aug 2013 07:30am EDT 

Nuvo Research Inc announced that its U.S. licensee for Pennsaid (diclofenac sodium topical solution) 1.5% w/w and Pennsaid 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013. The FDA has indicated to Mallinckrodt that it expects to respond to the NDA by February 7, 2014. 

Company Quote

4.39
-0.03 -0.68%
6 May 2015